Long-term status of the Social Security Trust Funds : hearing before the Subcommittee on Social Security and Family Policy of the Committee on Finance, United States Senate, One Hundredth Congress, second session.

Item 1038-A, 1038-B (microfiche)

The status of the Hellgate Railroad Viaduct in New York City : hearing before the Subcommittee on Water Resources, Transportation and Infrastructure of the Committee on Environment and Public Works, United States Senate, One Hundred First Congress, second session, May 16, 1990.

Cover title.

Long-range estimates of the financial status of the old-age, survivors, and disability insurance program, 1983 /

"April 1984"

Man of color : an autobiography : a factual report on the status of the American Negro today /

"In this autobiography, [the author] tells us the events of his life over the past fifty years. It is, too, a brief history of Los Angeles from the turn of the century--certainly, as far as the Negroes in Los Angeles are in the picture"--Preface. Jamaican-born Somerville became a Los Angeles dentist deeply involved in the NAACP.

International Union of Pharmacology. LXIX. Status of the calcitonin gene-related peptide subtype 2 receptor

Historically, calcitonin gene-related peptide (CGRP) receptors have been divided into two classes, CGRP(1) and CGRP(2).After the cloning of calcitonin receptor-like receptor (CLR) and receptor activity-modifying proteins (RAMPs), it became clear that the CGRP(1) receptor was a complex between CLR and RAMP1. It is now apparent that the CGRP(2) receptor phenotype is the result of CGRP acting at receptors for amylin and adrenomedullin. Accordingly, the term "CGRP(2)" receptor should no longer be used, and the "CGRP(1)" receptor should be known as the "CGRP" receptor.

Outlook and application status of the Rolls-Royce Fuel Cell Systems SOFC

Rolls-Royce fuel cell systems is developing megawatt scale power systems based on solid oxide fuel cell technology. The hybrid design promises to meet challenging energy efficiency, cost and performance targets in a grid friendly fashion. Analysis and testing to date indicate that those targets can be met and enable a wealth of fuel cell applications to meet customer and existing grid and modern grid requirements. Working with a global development team, a series of laboratory tests and evaluations are completed and future field test and evaluation and demonstration planned.

Landscape status of the Ousteri Wetland, Puducherry, India

Ousteri Lake is popularly called Ousteri which is a word formed out of the fusion of Tamil words Oussudu (a proper noun) and eri (meaning a lake). Ousteri is an inter-state lake about 50 percent of its waterspread lies in Puducherry and the rest in Tamil Nadu of India. The landscape survey of the entire Ousteri Lake has been collected and reported in the article. Additionally provides feedback from all category of stakeholders to identify whether the Ousteri lake is worth to be recognised under Ramsar Convention or not.

Mutational Status of the TP53 Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial

PurposeTP53 mutations have been described in chronic lymphocytic leukemia (CLL) and have been associated with poor prognosis in retrospective studies. We aimed to address the frequency and prognostic value of TP53 abnormalities in patients with CLL in the context of a prospective randomized trial.Patients and MethodsWe analyzed 529 CLL samples from the LRF CLL4 (Leukaemia Research Foundation Chronic Lymphocytic Leukemia 4) trial (chlorambucil v fludarabine with or without cyclophosphamide) at the time of random assignment for mutations in the TP53 gene. TP53 mutation status was correlated with response and survival data.ResultsMutations of TP53 were found in 40 patients (7.6%), including 25 (76%) of 33 with 17p deletion and 13 (3%) of 487 without that deletion. There was no significant correlation between TP53 mutations and age, stage, IGHV gene mutations, CD38 and ZAP-70 expression, or any other chromosomal abnormality other than 17p deletion, in which concordance was high (96%). TP53 mutations were significantly associated with poorer overall response rates (27% v 83%; P <.001) and shorter progression-free survival (PFS) and overall survival (OS; 5-year PFS: 5% v 17%; 5-year OS: 20% v 59%; P <.001 for both). Multivariate analysis that included baseline clinical variables, treatment, and known adverse genetic factors confirmed that TP53 mutations have added prognostic value.ConclusionTP53 mutations are associated with impaired response and shorter survival in patients with CLL. Analysis of TP53 mutations should be performed in patients with CLL who have progressive disease before starting first-line treatment, and those with mutations should be selected for novel experimental therapies. J Clin Oncol 29: 2223-2229. (C) 2011 by American Society of Clinical Oncology